Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Rain Oncology stock price, quote, forecast and news

RAIN
US75082Q1058

Price

1.21
Today +/-
+0
Today %
+0 %
P

Rain Oncology stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Rain Oncology stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Rain Oncology stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Rain Oncology stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Rain Oncology's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Rain Oncology Stock Price History

DateRain Oncology Price
1/26/20241.21 undefined
1/25/20241.21 undefined

Rain Oncology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Rain Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Rain Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Rain Oncology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Rain Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Rain Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Rain Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Rain Oncology’s growth potential.

Rain Oncology Revenue, EBIT and net profit per share

DateRain Oncology RevenueRain Oncology EBITRain Oncology Net Income
2029e0 undefined0 undefined0 undefined
2028e0 undefined-36.72 M undefined0 undefined
2027e0 undefined-33.82 M undefined0 undefined
2026e0 undefined-30.11 M undefined0 undefined
2025e0 undefined-29.07 M undefined-26.72 M undefined
2024e0 undefined-23.77 M undefined-16.88 M undefined
2023e0 undefined-59.69 M undefined-54.92 M undefined
20220 undefined-77.14 M undefined-75.72 M undefined
20210 undefined-51.51 M undefined-51.39 M undefined
20200 undefined-13.79 M undefined-21.08 M undefined
20190 undefined-10.83 M undefined-10.9 M undefined

Rain Oncology Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20192020202120222023e2024e2025e2026e2027e2028e2029e
00000000000
-----------
-----------
00000000000
-10-13-51-77-59-23-29-30-33-360
-----------
-10-21-51-75-54-16-260000
-110.00142.8647.06-28.00-70.3762.50----
25.9725.9719.4127.990000000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Rain Oncology Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Rain Oncology is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2019202020212022
       
5.858.9140.2130.5
0000
0000
0000
0.50.663.1
6.359.5146.2133.6
700500600400
0000
400500300100
0000
0000
0.10.50.11.1
1.21.511.6
7.561147.2135.2
       
20.194.700
0.21.1220.5278.9
-17.5-38.6-90-165.7
00-0.1-0.2
0000
2.857.2130.4113
0.30.86.17.1
0.71.110.214.8
0.31.500
0000
0000
1.33.416.321.9
2.8000
0000
500400300200
3.30.40.30.2
4.63.816.622.1
7.461147135.1
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Rain Oncology provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Rain Oncology's financial health and stability.

Assets

Rain Oncology's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Rain Oncology must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Rain Oncology after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Rain Oncology's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2019202020212022
-10-21-51-75
0000
0000
0158
0883
0000
0000
-11-11-37-63
0000
0-5-11847
0-5-11847
0000
2600
06313356
26912153
---11.00-3.00
0000
-853-3437
-11.32-11.25-37.59-63.21
0000

Rain Oncology stock margins

The Rain Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rain Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rain Oncology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Rain Oncology's sales revenue. A higher gross margin percentage indicates that the Rain Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Rain Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Rain Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Rain Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Rain Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Rain Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Rain Oncology Margin History

Rain Oncology Gross marginRain Oncology Profit marginRain Oncology EBIT marginRain Oncology Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %

Rain Oncology Stock Sales Revenue, EBIT, Earnings per Share

The Rain Oncology earnings per share therefore indicates how much revenue Rain Oncology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Rain Oncology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Rain Oncology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Rain Oncology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Rain Oncology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Rain Oncology Revenue, EBIT and net profit per share

DateRain Oncology Sales per ShareRain Oncology EBIT per shareRain Oncology Earnings per Share
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined-0.73 undefined
2024e0 undefined0 undefined-0.46 undefined
2023e0 undefined0 undefined-1.51 undefined
20220 undefined-2.76 undefined-2.71 undefined
20210 undefined-2.65 undefined-2.65 undefined
20200 undefined-0.53 undefined-0.81 undefined
20190 undefined-0.42 undefined-0.42 undefined

Rain Oncology business model

Rain Oncology is one of the most popular companies on Eulerpool.com.

Rain Oncology Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Rain Oncology historical P/E ratio, EBIT, and P/S ratio.

Rain Oncology shares outstanding

The number of shares was Rain Oncology in 2023 — This indicates how many shares 27.99 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Rain Oncology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Rain Oncology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Rain Oncology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Rain Oncology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Rain Oncology.

Rain Oncology latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.28 -0.19  (32 %)2023 Q3
6/30/2023-0.52 -0.61  (-18.26 %)2023 Q2
3/31/2023-0.63 -0.56  (10.8 %)2023 Q1
12/31/2022-0.57 -0.7  (-22.83 %)2022 Q4
9/30/2022-0.7 -0.68  (2.73 %)2022 Q3
6/30/2022-0.68 -0.66  (2.55 %)2022 Q2
3/31/2022-0.71 -0.66  (7.33 %)2022 Q1
12/31/2021-0.57 -0.68  (-18.3 %)2021 Q4
9/30/2021-0.49 -0.7  (-42.68 %)2021 Q3
6/30/2021-0.61 -0.39  (36.03 %)2021 Q2
1
2

Eulerpool ESG Scorecard© for the Rain Oncology stock

Eulerpool World ESG Rating (EESG©)

28/ 100

🌱 Environment

29

👫 Social

38

🏛️ Governance

16

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Rain Oncology list of shareholders

%
Name
Stocks
Change
Date
9.69414 % BVF Partners L.P.3,526,72908/10/2023
7.01185 % Vellanki (Avanish)2,550,910-59,6183/1/2023
5.59250 % Samsara BioCapital, LLC2,034,552-226,1006/30/2023
3.16716 % Boxer Capital, L.L.C.1,152,21206/30/2023
2.76308 % Berger (Franklin Milan)1,005,20703/1/2023
2.55222 % BlackRock Institutional Trust Company, N.A.928,499855,2886/30/2023
2.48810 % The Vanguard Group, Inc.905,17124,0816/30/2023
11.06236 % Tang Capital Management, LLC4,024,486284,14510/13/2023
1.97777 % Polen Capital Management, LLC719,51308/31/2023
1.81239 % Acadian Asset Management LLC659,349656,5716/30/2023
1
2
3
4
5
...
10

Rain Oncology Executives and Management Board

Mr. Avanish Vellanki48
Rain Oncology Chairman of the Board, Chief Executive Officer, Co-Founder (since 2017)
Compensation 2.19 M
Dr. Robert Doebele52
Rain Oncology President, Co-Founder, Chief Scientific Officer Chief Medical Officer
Compensation 1.43 M
Mr. Franklin Berger73
Rain Oncology Lead Independent Director
Compensation 117,752
Mr. Tran Nguyen49
Rain Oncology Independent Director
Compensation 94,252
Mr. Peter Radovich45
Rain Oncology Independent Director
Compensation 89,252
1
2

Most common questions regarding Rain Oncology

What is the P/E ratio of Rain Oncology 2024?

The Rain Oncology P/E ratio is -2.01.

What is the P/S ratio of Rain Oncology 2024?

The Rain Oncology P/S ratio is 0.

What is the AlleAktien quality score of Rain Oncology?

The AlleAktien quality score for Rain Oncology is 2/10.

What is the revenue of Rain Oncology 2024?

The revenue cannot currently be calculated for Rain Oncology.

How high is the profit of Rain Oncology 2024?

The expected Rain Oncology profit is -16.88 M USD.

What is the business model of Rain Oncology

No history available for Rain Oncology.

What is the Rain Oncology dividend?

Rain Oncology pays a dividend of 0 USD distributed over payouts per year.

How often does Rain Oncology pay dividends?

The dividend cannot currently be calculated for Rain Oncology or the company does not pay out a dividend.

What is the Rain Oncology ISIN?

The ISIN of Rain Oncology is US75082Q1058.

What is the Rain Oncology ticker?

The ticker of Rain Oncology is RAIN.

How much dividend does Rain Oncology pay?

Over the past 12 months, Rain Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rain Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Rain Oncology?

The current dividend yield of Rain Oncology is .

When does Rain Oncology pay dividends?

Rain Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rain Oncology?

Rain Oncology paid dividends every year for the past 0 years.

What is the dividend of Rain Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rain Oncology located?

Rain Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rain Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rain Oncology from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Rain Oncology pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Rain Oncology in the year 2023?

In the year 2023, Rain Oncology distributed 0 USD as dividends.

In which currency does Rain Oncology pay out the dividend?

The dividends of Rain Oncology are distributed in USD.

All fundamentals about Rain Oncology

Our stock analysis for Rain Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rain Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.